Tolterodine Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Tolterodine
Therapeutic Class: Anti-cholinergic (Antimuscarinic Agent)
Subclass: Urinary Antispasmodic
Speciality: Urology
Schedule (India): Schedule H
Route(s): Oral
Formulations Available in India:
- Tolterodine tartrate 1 mg immediate-release tablets
- Tolterodine tartrate 2 mg immediate-release tablets
- Tolterodine tartrate 4 mg extended-release capsules (LA/ER/XL formulations)
Note: Extended-release 2 mg capsules have limited availability in India
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India):
Overactive Bladder (OAB) with Urge Urinary Incontinence, Urgency, and Frequency
Immediate-Release (IR) Formulation:
| Parameter | Recommendation |
|
Starting dose
|
2 mg twice daily |
|
Titration
|
Reduce to 1 mg twice daily if not tolerated |
|
Usual maintenance dose
|
1–2 mg twice daily |
|
Maximum dose
|
4 mg/day (2 mg BD) |
Extended-Release (ER/LA) Formulation:
| Parameter | Recommendation |
|
Starting dose
|
4 mg once daily |
|
Titration
|
Reduce to 2 mg once daily if adverse effects occur (where 2 mg ER available) |
|
Usual maintenance dose
|
4 mg once daily |
|
Maximum dose
|
4 mg/day |
Clinical Notes:
- ER formulation preferred due to lower incidence of dry mouth and better compliance
- Swallow ER capsules whole; do not crush or chew
- Therapeutic effect may take 4–8 weeks to establish
- Evaluate response after 8–12 weeks; consider alternative if inadequate
- Not effective for stress urinary incontinence
Secondary Indications — Adults (Off-label):
| Indication | Dose | Duration | Notes |
| Neurogenic detrusor overactivity (spinal cord injury, multiple sclerosis) | IR: 2 mg BD or ER: 4 mg OD | Chronic; individualised |
OFF-LABEL; Specialist only (Urology/Neurology); Based on international studies and tertiary center practice in India
|
PAEDIATRIC DOSING (Specialist Only)
Primary Indications:
Not approved for routine paediatric use in India. Limited data available; use only under specialist supervision.
Neurogenic Detrusor Overactivity (OFF-LABEL)
| Age/Weight | Dose | Frequency | Maximum |
| ≥5 years and ≥20 kg | 0.1 mg/kg/day | Divided into 2 doses (IR formulation) | 2 mg twice daily |
| >12 years | Adult dosing may be considered | As per adult protocol | 4 mg/day |
Clinical Notes:
- ER formulation not routinely recommended in children
- Use IR tablets only
- Specialist supervision mandatory (paediatric urologist/nephrologist)
Safety Monitoring:
- Monitor for anticholinergic effects (dry mouth, constipation, urinary retention)
- Assess cognitive function and behaviour
- Regular post-void residual measurement
Secondary Indications — Paediatrics (Off-label):
| Indication | Dose | Duration | Notes |
| Overactive bladder in cerebral palsy/spina bifida | 0.1–0.2 mg/kg/day in 2 divided doses | Chronic with periodic reassessment |
OFF-LABEL; Specialist only; Urodynamic monitoring every 6–12 months; Based on open-label studies and tertiary Indian paediatric urology practice
|
Minimum Age: Not recommended below 5 years except under specialist supervision
RENAL ADJUSTMENT
| Renal Function | Recommendation |
| eGFR ≥30 mL/min/1.73m² | No dose adjustment required |
| eGFR 10–30 mL/min/1.73m² | IR: 1 mg twice daily; ER: 2 mg once daily (if available) or avoid ER |
| eGFR <10 mL/min/1.73m² | Avoid; if essential, use IR 1 mg BD under specialist supervision |
| Haemodialysis | Limited data; use with caution; not significantly dialysed |
HEPATIC ADJUSTMENT
| Severity | Recommendation |
|
Mild impairment (Child-Pugh A)
|
No dose adjustment required |
|
Moderate impairment (Child-Pugh B)
|
IR: 1 mg twice daily; ER: 2 mg once daily (if available); close monitoring |
|
Severe impairment (Child-Pugh C)
|
Avoid use; significantly reduced clearance |
CONTRAINDICATIONS
- Known hypersensitivity to tolterodine or formulation excipients
- Urinary retention (acute or chronic)
- Gastric retention or severe gastroparesis
- Uncontrolled narrow-angle (angle-closure) glaucoma
- Myasthenia gravis
- Severe ulcerative colitis or toxic megacolon
CAUTIONS
- Elderly patients (≥65 years): Increased anticholinergic sensitivity
- Bladder outflow obstruction (including prostatic hypertrophy): Risk of urinary retention
- Gastrointestinal obstructive disorders
- Constipation or history of decreased GI motility
- Controlled narrow-angle glaucoma (with ophthalmologist clearance)
- Hepatic or renal impairment
- Cardiac disease: Risk of QT prolongation (especially in CYP2D6 poor metabolisers)
- Autonomic neuropathy
- Hiatus hernia with reflux oesophagitis
- Concomitant use with other anticholinergic medications
- Hot environment exposure (risk of decreased sweating)
PREGNANCY
| Aspect | Recommendation |
|
Risk category
|
Limited human data; animal studies suggest potential risk |
|
Preferred alternatives
|
Non-pharmacological measures (bladder training, pelvic floor exercises) preferred; if drug needed, oxybutynin has more experience |
|
When to use
|
Only if benefit clearly outweighs risk; specialist input essential |
|
What to monitor
|
Maternal: Urinary retention, dry mouth; Fetal: Growth monitoring if prolonged use |
LACTATION
| Aspect | Recommendation |
|
Compatibility
|
Limited data; likely low transfer to milk |
|
Preferred alternatives
|
Non-pharmacological measures; oxybutynin if drug required (more safety data) |
|
Expected drug level in milk
|
Low (based on physicochemical properties) |
|
What to monitor in infant
|
Sedation, feeding difficulties, dry mouth, constipation, irritability |
ELDERLY
| Aspect | Recommendation |
|
Recommended starting dose
|
IR: 1 mg twice daily; ER: 2 mg once daily (if available) or 4 mg OD with close monitoring |
|
Titration
|
Slower; increase only if tolerated and needed |
|
Extra risks
|
Confusion, cognitive decline, falls, dry mouth, constipation, urinary retention, blurred vision, heat stroke |
|
Special precautions
|
Regular cognitive assessment; review anticholinergic burden from all medications; consider alternatives like mirabegron in those with cognitive concerns |
MAJOR DRUG INTERACTIONS
| Interacting Drug/Class | Mechanism | Clinical Effect | Recommendation |
|
Potent CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir)
|
Inhibit metabolism | Increased tolterodine levels; enhanced adverse effects | Reduce dose to IR 1 mg BD or ER 2 mg OD; avoid ER 4 mg |
|
Other anticholinergics (TCAs, antihistamines, antipsychotics)
|
Additive pharmacodynamic effect | Central and peripheral anticholinergic toxicity | Avoid combination or minimize doses; monitor for cognitive effects |
|
QT-prolonging drugs (amiodarone, sotalol, haloperidol, ondansetron)
|
Additive QT prolongation | Risk of torsades de pointes | Avoid combination; if unavoidable, obtain baseline ECG and monitor |
|
Potassium chloride (slow-release oral forms)
|
Reduced GI motility | GI mucosal injury | Avoid combination |
MODERATE DRUG INTERACTIONS
| Interacting Drug/Class | Clinical Effect | Recommendation |
|
CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine)
|
Increased tolterodine exposure in extensive metabolisers | Monitor for enhanced side effects; ER form may be better tolerated |
|
CYP3A4 inducers (rifampicin, carbamazepine, phenytoin)
|
Reduced tolterodine efficacy | May need higher dose or alternative agent; monitor response |
|
Cholinesterase inhibitors (donepezil, rivastigmine)
|
Pharmacodynamic antagonism | Reduced efficacy of both; avoid if possible in dementia patients |
|
Metoclopramide
|
Opposing GI effects | Reduced efficacy of metoclopramide |
|
Digoxin
|
No direct interaction but both used in elderly | Monitor for additive effects on heart rate |
COMMON ADVERSE EFFECTS
- Dry mouth (most common; up to 40% with IR, lower with ER)
- Constipation
- Headache
- Dyspepsia
- Abdominal pain
- Blurred vision
- Dry eyes
- Fatigue or drowsiness
- Dizziness
- Urinary tract infection
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Clinical Significance |
|
Acute urinary retention
|
Discontinue immediately; may require catheterisation |
|
QT prolongation / Arrhythmia
|
Baseline ECG in high-risk patients; discontinue if significant prolongation |
|
Cognitive impairment / Delirium
|
Especially in elderly; requires immediate discontinuation |
|
Angioedema / Anaphylaxis
|
Rare hypersensitivity; discontinue and provide emergency treatment |
|
Hallucinations
|
More common in elderly or those with CNS disease; discontinue |
|
Heat stroke
|
Due to reduced sweating; counsel patients about hot environments |
MONITORING REQUIREMENTS
| Phase | Parameters |
|
Baseline
|
Renal function (eGFR); hepatic function (LFTs); ECG if cardiac risk or on QT-prolonging drugs; post-void residual volume if outflow obstruction suspected; cognitive assessment in elderly |
|
After initiation / dose change
|
Assess for urinary retention (within 1–2 weeks); bowel function; dry mouth severity; cognitive function in elderly |
|
Long-term
|
Periodic reassessment of symptom control (bladder diary); post-void residual if symptoms change; cognitive assessment every 6–12 months in elderly; reassess need for continued therapy annually |
BRANDS AVAILABLE IN INDIA
| Brand Name | Manufacturer | Formulation |
| Detrusitol | Upjohn (Pfizer) | IR 1 mg, 2 mg tablets |
| Terol | Cipla | IR 1 mg, 2 mg tablets |
| Terol LA | Cipla | ER 4 mg capsules |
| Roliten | Intas | IR 1 mg, 2 mg tablets |
| Urotol | Mankind | IR 2 mg tablets |
Note: Multiple generic equivalents available; ER formulations commonly labelled as LA, XL, or SR
PRICE RANGE (INR)
| Formulation | Price Range | Notes |
| IR 1 mg tablet | ₹4–₹10 per tablet | — |
| IR 2 mg tablet | ₹6–₹15 per tablet | — |
| ER 4 mg capsule | ₹12–₹35 per capsule | — |
|
NLEM status
|
Not included in NLEM 2022 | — |
|
Availability
|
Private pharmacies; limited government supply | — |
CLINICAL PEARLS
- ER formulation preferred: Once-daily dosing improves compliance and has lower incidence of dry mouth compared to IR formulation
- Dry mouth management: Sugar-free lozenges, frequent sips of water; if severe, consider switching to mirabegron (beta-3 agonist)
- Not for stress incontinence: Tolterodine is effective only for urgency and urge incontinence; not useful for stress urinary incontinence
- Elderly caution: Regularly assess cognitive function; tolterodine contributes to anticholinergic burden; consider mirabegron as alternative in cognitively at-risk patients
- Duration of trial: Allow 4–8 weeks for therapeutic effect; if no benefit at maximum dose after 8–12 weeks, reconsider diagnosis or switch therapy
- Post-void residual: Check before initiating in patients with prostatic enlargement or symptoms suggestive of incomplete voiding
TAGS
tolterodine; overactive-bladder; urinary-incontinence; antimuscarinic; urinary-antispasmodic; elderly-caution; CYP3A4-substrate; renal-adjustment; urology; OAB
VERSION
RxIndia v1.0 — 03 Feb 2026
REFERENCES
- CDSCO approved prescribing information
- Indian Pharmacopoeia / National Formulary of India
- API Textbook of Medicine
- AIIMS Urology Department protocols
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics
- Harrison’s Principles of Internal Medicine
- Indian Uro-Gynaecology Society practice guidelines
- International RCTs/meta-analyses (for off-label paediatric use evidence)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.